US 11,732,054 B2
Anti-CD3 antibodies and methods of use
Xiaocheng Chen, Foster City, CA (US); Mark S. Dennis, San Carlos, CA (US); Allen J. Ebens, Jr., San Carlos, CA (US); Teemu T. Junttila, San Mateo, CA (US); Robert F. Kelley, Petaluma, CA (US); and Mary A. Mathieu, San Francisco, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Feb. 13, 2020, as Appl. No. 16/790,656.
Application 16/790,656 is a division of application No. 15/473,242, filed on Mar. 29, 2017, granted, now 10,640,572.
Application 15/473,242 is a division of application No. 14/574,132, filed on Dec. 17, 2014, granted, now 10,174,124, issued on Jan. 8, 2019.
Claims priority of provisional application 62/091,441, filed on Dec. 12, 2014.
Claims priority of provisional application 62/053,582, filed on Sep. 22, 2014.
Claims priority of provisional application 62/026,594, filed on Jul. 18, 2014.
Claims priority of provisional application 61/949,950, filed on Mar. 7, 2014.
Claims priority of provisional application 61/917,346, filed on Dec. 17, 2013.
Prior Publication US 2020/0299409 A1, Sep. 24, 2020
Int. Cl. C07K 16/28 (2006.01); C07K 16/32 (2006.01); A61K 39/395 (2006.01); C07K 16/30 (2006.01); A61K 45/06 (2006.01); A61K 31/573 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01)
CPC C07K 16/32 (2013.01) [A61K 31/573 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6881 (2017.08); C07K 16/283 (2013.01); C07K 16/2809 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/71 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 56 Claims
 
1. A method of treating or delaying progression of a HER2-positive cancer in a subject, the method comprising administering to the subject an effective amount of a bispecific antibody that binds to HER2 and CD3, wherein the bispecific antibody comprises
(a) an anti-HER2 arm comprising a first binding domain, the first binding domain comprising:
a hypervariable region (HVR)-H1 comprising the amino acid sequence of SEQ ID NO: 169,
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 170,
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 171,
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 172,
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 173, and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 174; and
(b) an anti-CD3 arm comprising a second binding domain, the second binding domain comprising:
an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1,
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2,
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3,
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4,
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6.